Ajanta Pharma 관리
관리 기준 확인 1/4
We currently do not have sufficient information about the CEO.
주요 정보
Yogesh Agrawal
최고 경영자
₹216.0m
총 보상
| CEO 급여 비율 | 57.2% |
| CEO 임기 | 16.9yrs |
| CEO 소유권 | 14.5% |
| 경영진 평균 재임 기간 | 데이터 없음 |
| 이사회 평균 재임 기간 | 6yrs |
최근 관리 업데이트
Recent updates
Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Oct 31
Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Sep 10We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Aug 23Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 04Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E
Aug 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Jun 01Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price
Apr 05We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
Dec 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Oct 24Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Aug 25Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?
Jul 19A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Apr 28Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut
Feb 06Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Dec 13Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50
Oct 31Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching
Sep 22Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?
Sep 08Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet
Jul 07Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?
Jun 14Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?
May 15Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 10Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 11Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?
Feb 24The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On
Jan 30
What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?
Jan 18Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Jan 06CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹9b |
| Jun 30 2024 | n/a | n/a | ₹9b |
| Mar 31 2024 | ₹216m | ₹124m | ₹8b |
| Dec 31 2023 | n/a | n/a | ₹7b |
| Sep 30 2023 | n/a | n/a | ₹7b |
| Jun 30 2023 | n/a | n/a | ₹6b |
| Mar 31 2023 | ₹156m | ₹112m | ₹6b |
| Dec 31 2022 | n/a | n/a | ₹6b |
| Sep 30 2022 | n/a | n/a | ₹7b |
| Jun 30 2022 | n/a | n/a | ₹7b |
| Mar 31 2022 | ₹163m | ₹94m | ₹7b |
| Dec 31 2021 | n/a | n/a | ₹7b |
| Sep 30 2021 | n/a | n/a | ₹7b |
| Jun 30 2021 | n/a | n/a | ₹7b |
| Mar 31 2021 | ₹128m | ₹75m | ₹7b |
| Dec 31 2020 | n/a | n/a | ₹6b |
| Sep 30 2020 | n/a | n/a | ₹6b |
| Jun 30 2020 | n/a | n/a | ₹5b |
| Mar 31 2020 | ₹107m | ₹66m | ₹5b |
| Dec 31 2019 | n/a | n/a | ₹4b |
| Sep 30 2019 | n/a | n/a | ₹4b |
| Jun 30 2019 | n/a | n/a | ₹4b |
| Mar 31 2019 | ₹99m | ₹61m | ₹4b |
| Dec 31 2018 | n/a | n/a | ₹4b |
| Sep 30 2018 | n/a | n/a | ₹5b |
| Jun 30 2018 | n/a | n/a | ₹5b |
| Mar 31 2018 | ₹44m | ₹13m | ₹5b |
보상 대 시장: Yogesh's total compensation ($USD2.57M) is above average for companies of similar size in the Indian market ($USD589.84K).
보상과 수익: Yogesh's compensation has increased by more than 20% in the past year.
CEO
Yogesh Agrawal (52 yo)
16.9yrs
테뉴어
₹215,960,000
보상
Mr. Yogesh Mannalal Agrawal, M.B.A, has been Managing Director at Ajanta Pharma Ltd. since December 14, 2007. Mr. Agrawal is handling global business of Ajanta Pharma Ltd.He has handled various aspects of...
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| MD & Executive Director | 24.6yrs | ₹215.96m | 14.48% ₹ 54.0b | |
| Joint MD & Director | 11.6yrs | ₹215.96m | 14.48% ₹ 54.0b | |
| Executive Vice Chairman of the Board | 26.9yrs | ₹42.04m | 데이터 없음 | |
| Director of Ajanta Pharma USA Inc. | no data | ₹25.50m | 데이터 없음 | |
| Chairman of the Board | 44.9yrs | ₹777.00k | 데이터 없음 | |
| Independent Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Director of Ajanta Pharma Philippines Inc. | no data | 데이터 없음 | 데이터 없음 | |
| Director of Ajanta Pharma (Mauritius) Ltd. | no data | 데이터 없음 | 데이터 없음 | |
| Director of Ajanta Pharma (Mauritius) Ltd. | no data | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 |
6.0yrs
평균 재임 기간
68yo
평균 연령
경험이 풍부한 이사회: AJANTPHARM's board of directors are considered experienced (6 years average tenure).